

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/445, 31/165, 31/13</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/25350</b> <b>(43) International Publication Date:</b> 27 May 1999 (27.05.99)
<b>(21) International Application Number:</b> PCT/US98/21423 <b>(22) International Filing Date:</b> 9 October 1998 (09.10.98)  <b>(30) Priority Data:</b> 60/065,694 14 November 1997 (14.11.97) US  <b>(71) Applicant (for all designated States except US):</b> ALCON LABORATORIES, INC. [US/US]; 6201 South Freeway, Fort Worth, TX 76134-2099 (US).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> DESANTIS, Louis, Jr. [US/US]; 2316 Winton Terrace West, Fort Worth, TX 76109 (US).  <b>(74) Agents:</b> YEAGER, Sally, S. et al.; R & D Counsel Q-148, Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, TX 76134-2099 (US).	<b>(81) Designated States:</b> AU, BR, CA, CN, JP, KR, MX, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> TREATMENT OF DIABETIC RETINOPATHY  <b>(57) Abstract</b>  The use of compositions of antagonists of glutamate induced excitotoxicity for the treatment of diabetic retinopathy is disclosed.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

## TREATMENT OF DIABETIC RETINOPATHY

10 This invention relates to the use of suitable antagonists of glutamate-induced excitotoxicity for the treatment of diabetic retinopathy, particularly that of the proliferative type.

### Background of the Invention

15

Ambati, et al., "Elevated GABA, Glutamate, and VEGF in the Vitreous of Humans With Proliferative Diabetic Retinopathy," *Invest. Ophthalmol. Vis. Sci.*, 38:S771, 1997, reported elevated levels of glutamate in vitreous samples obtained from patients with proliferative diabetic retinopathy who underwent pars plana vitrectomy. They suggested that these levels of glutamate are potentially toxic to retinal ganglion cells.

25

Lieth, et al., "Glial Glutamate to Glutamine Conversion is Impaired in Retinas of Diabetic Rats," *Invest. Ophthalmol. Vis. Sci.*, 38:S695, 1997, reported that glial glutamate to glutamine conversion is impaired in the retinas of diabetic rats.

30

Hudson, et al., "Short-Wavelength and White-on-White Automated Static Perimetry in Patients With Clinically Significant Diabetic Macular Oedema (DMO)," *Invest. Ophthalmol. Vis. Sci.*, 38:S768, 1997, reported deficits in retinal function related to ganglion cell function in patients with diabetic macular edema.

35

Panretinal photocoagulation and the dietary and/or pharmacological control of hyperglycemia are the only methods currently in use to treat diabetic retinopathy. Vision loss is associated with the use of panretinal photocoagulation. Consequently, there is a need for new ways for treating diabetic retinopathy. The present compositions and methods fill that need.

### **Summary of the Invention**

The present invention is directed to compositions and methods for treating diabetic retinopathy using an antagonist of the excitatory amino acid receptors involved in glutamate-induced excitotoxicity. In particular, N-methyl-D-aspartate (NMDA) receptor antagonists and more particularly antagonists of the polyamine receptor are useful for treating diabetic retinopathy.

### **Description of Preferred Embodiments**

This invention provides a pharmacological method for preventing further damage to retinal ganglion cells resulting from diabetes and associated with glutamate-induced excitotoxicity. It is expected to be used instead of panretinal photocoagulation and thus avoid the near-term loss of vision that accompanies such photocoagulation.

The invention is a treatment for diabetic retinopathy, particularly of the proliferative type, comprising the local or systemic administration of a suitable antagonist of the excitatory amino acid receptors involved in glutamate-induced excitotoxicity. The purpose is to prevent damage to retinal ganglion cells resulting from the excitotoxic effects produced by excessive glutamate found in the retinas of patients who have proliferative diabetic retinopathy. A suitable glutamate antagonist is one which has the appropriate physicochemical properties to allow it to gain access to the site of action, i.e., the retina, following administration, either locally to the eye or systemically, of a pharmaceutically effective amount of such antagonist. The glutamate antagonist can work directly or indirectly to prevent the sequence of cellular events that ensues from the action of glutamate upon excitatory amino acid receptors at which glutamate can act. Glutamate receptors are classified as NMDA and non-NMDA receptors.

This invention includes antagonists that act on NMDA and non-NMDA receptors for glutamate. Particularly preferred antagonists are those which act on the NMDA receptor-calcium channel complex. Such antagonists may act by competing with glutamate at the receptor site, may act at one or all of several regulatory or modulatory sites associated with the NMDA receptor-calcium channel complex, or can inhibit one or more of the downstream effects that result from activation of the NMDA receptor-calcium channel complex. Examples include, but are not limited to, polyamine site antagonists, receptor antagonists (compete with NMDA), and channel blockers that operate uncompetitively to block the NMDA receptor channel.

Polyamine site antagonists are particularly useful according to this invention. Examples of specific examples are set out in U.S. Patent No. 4,690,931, which is incorporated herein by reference. The most preferred compounds in the patent are 2-[4-(4-fluorobenzyl)-piperidino]-1-(4-chlorophenyl)ethanol, also known as eliprodil and 2-(4-benzylpiperidino)-1-(4-hydroxyphenyl)-propanol, also known as ifenprodil.

Other compounds which are particularly useful include remacemide and memantine.

Because the site of action is located within the eye, which is normally protected by the blood-ocular barriers (i.e., blood-aqueous humor and blood-retinal barriers), it is preferred that the antagonist be able to cross these barriers to reach the site of action. Alternatively, the antagonist could be given intraocularly or periocularly by an acceptable method to deliver the antagonist to its site of action. All modes of delivery that result in placing the antagonist at its site of action are contemplated.

In general, the antagonists useful in the present invention will be administered orally. Daily dosage of these compounds will range between about 0.1 and about 500 milligrams (mg), preferably between about 5 and about 100 mg. Local administration of these compounds will require a dosage range of between about 0.1 and about 50 mg, preferably between about 0.5 and about 5 mg. An aqueous composition will generally contain between about 0.1 and about 10 percent by weight (wt%) of the active, preferably between about 1 and about 5 wt%.

**I Claim:**

1. A composition for treating diabetic retinopathy comprising a pharmaceutically effective amount of an antagonist of glutamate-induced excitotoxicity.

5

2. The composition of Claim 1 wherein the antagonist is selected from the group consisting of polyamine site antagonists, NMDA receptor antagonists, and channel blockers which operate uncompetitively to block the NMDA receptor channel.

10

3. The composition of Claim 2 wherein the antagonist is a polyamine site antagonist.

4. The composition of Claim 3 wherein the polyamine site antagonist is eliprodil.

15

5. A method for treating diabetic retinopathy which comprises, administering a pharmaceutically effective amount of an antagonist of glutamate-induced excitotoxicity.

6. The method of Claim 5 wherein the antagonist is selected from the group consisting of polyamine site antagonists, NMDA receptor antagonists, and channel blockers which operate uncompetitively to block the NMDA receptor channel.

20

7. The method of Claim 6 wherein the antagonist is a polyamine site antagonist.

8. The method of Claim 7 wherein the polyamine site antagonist is eliprodil.

25

# INTERNATIONAL SEARCH REPORT

Inte onal Application No  
PCT/US 98/21423

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/445 A61K31/165 A61K31/13

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 521 215 A (KLOOG YOEL ET AL) 28 May 1996	1,2,5,6
Y	see column 6, line 30 - line 39 see column 7, line 19 - line 33 see column 9; table 1 ---	3,4,7,8
X	FR 2 738 568 A (SYNTHELABO) 14 March 1997	1-3,5-7
Y	see page 19, line 36 - line 39 see page 20, line 21 - line 22 see page 22, line 8 - line 10 see page 22, line 26 - line 27 ---	4,8
X	WO 90 06118 A (HOUSTON BIOTECHNOLOGY ;SQUIBB & SONS INC (US)) 14 June 1990	1,2,5,6
Y	see page 2, line 26 - line 28 see page 5, line 1 - line 14 see example 5 --- -/--	3,4,7,8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 December 1998

Date of mailing of the international search report

22/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Villa Riva, A

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/21423

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 01339 A (ALLERGAN INC) 16 January 1997 see page 10, line 5 - line 10 see page 10, line 30 - page 11, line 8 see example 1 see claim 4 see figure 1 ---	1,2,5,6
X	--- LANGEVIN J. ET AL.: "Etude du tartrate d' ifenprodil dans le traitement des accidents vasculaires cérébraux aigus" OUEST MÉDICAL, vol. 29, 1976, pages 853-854, XP002088157	1-3,5-7
Y	see page 854, left-hand column, line 40 - line 42 ---	4,8
X	--- DATABASE WPI Section Ch, Week 9802 Derwent Publications Ltd., London, GB; Class B02, AN 98-018014 XP002088198 & WO 97 38691 A (SUMITOMO PHARM CO LTD) , 23 October 1997	1,2,5,6
Y	see abstract ---	7,8
Y	KAPIN M A ET AL: "PROTECTIVE EFFECTS OF THE POLYAMINE ANTAGONIST, ELIPRODIL HYDROCHLORIDE IN RETINA SUBJECTED TO AN EXITOTOXIC-OR ISCHEMIC- INSULT" SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 22, no. 1 - 03, 16 November 1996, page 1279 XP000677227	7,8
X	see abstract -----	3,4



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/21423

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5521215 A	28-05-1996	IL 92238 A	31-07-1995
		US 5284867 A	08-02-1994
		AU 690221 B	23-04-1998
		AU 1743395 A	21-08-1995
		CA 2183466 A	10-08-1995
		EP 0765160 A	02-04-1997
		JP 9511493 T	18-11-1997
		SG 49625 A	15-06-1998
		WO 9520958 A	10-08-1995
		AT 119898 T	15-04-1995
		AU 631262 B	19-11-1992
		AU 6583490 A	30-05-1991
		CA 2029419 A	08-05-1991
		DE 69017839 D	20-04-1995
		DE 69017839 T	31-08-1995
		DK 427518 T	24-07-1995
		EP 0427518 A	15-05-1991
		ES 2071786 T	01-07-1995
		JP 2038059 C	28-03-1996
		JP 3209377 A	12-09-1991
		JP 7068235 B	26-07-1995
		KR 9505914 B	07-06-1994
FR 2738568 A	14-03-1997	AU 6934496 A	27-03-1997
		CZ 9800665 A	17-06-1998
		EP 0848707 A	24-06-1998
		WO 9709309 A	13-03-1997
		NO 981000 A	08-05-1998
		PL 325421 A	20-07-1998
WO 9006118 A	14-06-1990	AU 4754790 A	26-06-1990
		AU 4807790 A	26-06-1990
		CA 2004616 A	05-06-1990
		CA 2004617 A	05-06-1990
		WO 9006123 A	14-06-1990
WO 9701339 A	16-01-1997	AU 6386496 A	30-01-1997
		CA 2225626 A	16-01-1997
		EP 0835110 A	15-04-1998

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**